학술논문

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
Document Type
Abstract
Source
In Clinical Lymphoma Myeloma and Leukemia February 2017 17(1) Supplement:e14-e15
Subject
Language
ISSN
2152-2650